Justices Won't Review Invalidation Of Bristol-Myers Patent
The U.S. Supreme Court on Monday declined to hear Bristol-Myers Squibb Co.'s challenge to a Federal Circuit ruling that upheld the invalidation of the patent on its hepatitis B drug Baraclude....To view the full article, register now.
Already a subscriber? Click here to view full article